1. Home
  2. MCBS vs CSTL Comparison

MCBS vs CSTL Comparison

Compare MCBS & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MetroCity Bankshares Inc.

MCBS

MetroCity Bankshares Inc.

N/A

Current Price

$28.58

Market Cap

816.1M

Sector

Finance

ML Signal

N/A

Logo Castle Biosciences Inc.

CSTL

Castle Biosciences Inc.

N/A

Current Price

$27.97

Market Cap

940.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MCBS
CSTL
Founded
2006
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
816.1M
940.8M
IPO Year
2019
2019

Fundamental Metrics

Financial Performance
Metric
MCBS
CSTL
Price
$28.58
$27.97
Analyst Decision
Hold
Strong Buy
Analyst Count
1
6
Target Price
$31.00
$47.17
AVG Volume (30 Days)
60.2K
425.2K
Earning Date
05-01-2026
05-18-2026
Dividend Yield
3.51%
N/A
EPS Growth
24.75
N/A
EPS
1.96
N/A
Revenue
N/A
$344,229,000.00
Revenue This Year
$36.76
N/A
Revenue Next Year
$4.83
$13.71
P/E Ratio
$14.56
N/A
Revenue Growth
N/A
3.66
52 Week Low
$24.24
$14.59
52 Week High
$31.00
$44.28

Technical Indicators

Market Signals
Indicator
MCBS
CSTL
Relative Strength Index (RSI) 44.28 28.16
Support Level $26.90 $21.77
Resistance Level $29.00 $34.97
Average True Range (ATR) 0.68 1.73
MACD -0.17 -0.26
Stochastic Oscillator 17.29 2.24

Price Performance

Historical Comparison
MCBS
CSTL

About MCBS MetroCity Bankshares Inc.

MetroCity Bankshares Inc is a holding company of its subsidiary Metro City Bank. It provides commercial banking services such as consumer and commercial checking accounts, savings accounts, certificates of deposits, commercial and consumer loans, money transfers and a variety of other banking services. The banks generate revenue from interest income. Its customers include small business owners, professionals, consumers, and real estate developers.

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.

Share on Social Networks: